4//SEC Filing
Gibbs Michael Terrence 4
Accession 0000899243-23-007725
CIK 0001492674other
Filed
Mar 8, 7:00 PM ET
Accepted
Mar 9, 4:00 PM ET
Size
14.1 KB
Accession
0000899243-23-007725
Insider Transaction Report
Form 4
Gibbs Michael Terrence
General Counsel
Transactions
- Sale
Common Stock
2023-02-28$0.59/sh−1,585$935→ 6,517 total - Sale
Common Stock
2023-02-22$0.65/sh−2,145$1,394→ 5,188 total - Exercise/Conversion
Common Stock
2023-02-24+2,914→ 8,102 total - Exercise/Conversion
Restricted Stock Units
2023-02-24−2,914→ 2,914 total→ Common Stock (2,914 underlying) - Exercise/Conversion
Common Stock
2023-02-20+4,000→ 7,333 total - Exercise/Conversion
Restricted Stock Units
2023-02-20−4,000→ 8,000 total→ Common Stock (4,000 underlying)
Footnotes (4)
- [F1]Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
- [F2]The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 11, 2018.
- [F3]On February 20, 2022 the reporting person was granted 12,000 RSU's that vest in three equal annual installments commencing on February 20, 2023
- [F4]On February 24, 2021 the reporting person was granted 8,743 RSU's that vest in three equal annual installments commencing on February 24, 2022.
Documents
Issuer
T2 Biosystems, Inc.
CIK 0001492674
Entity typeother
Related Parties
1- filerCIK 0001665000
Filing Metadata
- Form type
- 4
- Filed
- Mar 8, 7:00 PM ET
- Accepted
- Mar 9, 4:00 PM ET
- Size
- 14.1 KB